The full tirzepatide timeline shows that results continue to accumulate even late in the treatment course, just at a slower pace
The AWARD-6 trial (N=599) showed dulaglutide 1.5 mg was non-inferior to liraglutide 1.8 mg for HbA1c reduction (-1.42% vs
Skin Pharmacology and Physiology (2011)
I started in April, now it's July, and I think it was a really healthy pace
This evaluation ought to account for age, sex, family history, prior medical history, environmental exposures, and other established risk determinants that may increase the likelihood of occult malignancy
Considered the least bio-active and thus the least effective for supplementation